The FDA-approved drug rapamycin and its analogues (rapalogs) are inhibitors of the mechanistic target of rapamycin (mTOR). mTOR inhibitors are an exceptionally well-explored therapeutic class, encompassing three FDA-approved medications evaluated in more than 3,000 clinical trials. Recent studies have demonstrated that mTOR inhibitors extend health and life span in multiple organisms, including yeast, worms, flies, and mice, establishing them as the best validated class of longevity therapeutics.
See press release
Tornado is developing structural analogues of rapamycin with novel selectivity profiles that are predicted to improve safety and efficacy. The most advanced asset is now moving into IND enabling studies, while a second asset is undergoing preclinical efficacy testing.
.png)
.svg)
.svg)